Hosted on MSN3mon
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene TherapiesArrowhead will remain responsible for the ongoing ... These programs target spinocerebellar ataxia type 1, spinocerebellar ataxia type 3 and Huntington's disease. As part of this deal, the ...
Hosted on MSN1mon
Arrowhead and Sarepta close $500 million licensing dealArrowhead Pharmaceuticals ... including treatments for facioscapulohumeral muscular dystrophy type 1, type 1 myotonic dystrophy, idiopathic pulmonary fibrosis, and spinocerebellar ataxia 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback